The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile
Version of Record online: 13 AUG 2013
© 2013 Federation of European Microbiological Societies. Published by John Wiley & Sons Ltd. All rights reserved
FEMS Microbiology Letters
Volume 347, Issue 1, pages 61–69, October 2013
How to Cite
Shah, Z., Mahbuba, R. and Turcotte, B. (2013), The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile. FEMS Microbiology Letters, 347: 61–69. doi: 10.1111/1574-6968.12223
- Issue online: 9 SEP 2013
- Version of Record online: 13 AUG 2013
- Accepted manuscript online: 26 JUL 2013 10:02AM EST
- Manuscript Accepted: 17 JUL 2013
- Manuscript Revised: 28 JUN 2013
- Manuscript Received: 29 APR 2013
- CIHR. Grant Number: MOP-84231
- NSERC. Grant Number: 184053-04
|fml12223-sup-0001-TablS1-S3.docx||Word document||90K||Table S1.|
Escherichia coli strains used in this study.
Table S2. Staphylococcus aureus strains used in this study.
Table S3. List of genes (encoding known or putative reductases) whose deletion results in resistance to TPZ. “+” indicates colony formation and “-” indicates complete absence of colony formation.
|fml12223-sup-0002-TablS4.xlsx||application/msexcel||60K||Table S4. List of E. coli strains (obtained from the Keio collection) that were tested for decreased susceptibility to TPZ.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.